EUVIMEDEUVIMED entdecken
Open Access

Personalizing Maintenance Rituximab in Follicular Lymphoma: A Machine Learning Framework for Risk–Benefit Optimization

Junyi Gao iD, Jiaxin Liu, Xinze Li, Meng Wu, Rongyi Cui, Yannan Huang, Zhixin Zhang, Yinghao Zhu, Yasha Wang, Yuqin Song, Ewen M Harrison, Lan Mi und 2 weitere

Health Data Science · 01.01.2026 · 6

DOI: 10.34133/hds.0467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Data Science, online erschienen am 12.08.2026. Verfasst von Junyi Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospita…. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While maintenance rituximab therapy (MT) for follicular lymphoma improves progression-free survival, individual benefit varies, creating a critical need to avoid overtreatment and its associated burdens.

Methods

We developed a double machine learning framework using a retrospective 404-patient cohort to estimate the individualized treatment effect of MT on the risk of disease progression within 24 months.

Results

Our model revealed heterogeneity in treatment benefit, successfully distinguishing patients most likely to benefit from those who are not. A retrospective simulated application identified a “low-risk, low-benefit” subgroup that might potentially forgo MT. Furthermore, aligning historical clinical decisions with our model’s recommendations was associated with a lower progression rate compared to nonalignment (14.8% vs. 38.0%). Extensive sensitivity analyses confirmed the robustness of this treatment heterogeneity against potential unmeasured confounding and temporal practice shifts.

Conclusions

Supported by an updated interactive clinical decision tool, this data-driven framework provides a robust strategy to personalize MT by separating prognostic risk from predictive benefit. It serves as a hypothesis-generating template to guide future prospective risk-adapted trials and reduce unnecessary treatment in oncology.

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK.
  • Health Data Research UK, London, UK.
  • National Engineering Research Center for Software Engineering, Peking University, Beijing, China.
  • Department of Automation, Tsinghua University, Beijing, China.

ORCID-Profile: Junyi Gao

Förderung

  • Wellcome Trust

Zitieren

APA

Gao, J., Liu, J., Li, X., Wu, M., Cui, R., Huang, Y., Zhang, Z., Zhu, Y., Wang, Y., Song, Y., Harrison, E. M., Mi, L., Ma, L., & Xie, Y. (2026). Personalizing Maintenance Rituximab in Follicular Lymphoma: A Machine Learning Framework for Risk–Benefit Optimization. Health Data Science, 6. https://doi.org/10.34133/hds.0467

Vancouver

Gao J, Liu J, Li X, Wu M, Cui R, Huang Y, et al. Personalizing Maintenance Rituximab in Follicular Lymphoma: A Machine Learning Framework for Risk–Benefit Optimization. Health Data Science. 2026;6. doi:10.34133/hds.0467

BibTeX
@article{Gao2026,
  author = {Gao, Junyi and Liu, Jiaxin and Li, Xinze and Wu, Meng and Cui, Rongyi and Huang, Yannan and Zhang, Zhixin and Zhu, Yinghao and Wang, Yasha and Song, Yuqin and Harrison, Ewen M and Mi, Lan and Ma, Liantao and Xie, Yan},
  title = {Personalizing Maintenance Rituximab in Follicular Lymphoma: A Machine Learning Framework for Risk–Benefit Optimization},
  journal = {Health Data Science},
  year = {2026},
  volume = {6},
  doi = {10.34133/hds.0467}
}
Kostenlos starten →